As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of durable clinical responses and acceptable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback